Predictive Biomarkers in Thyroid Cancer

Article Oncology

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes et al.

Summary: This study suggests that patients with rare cancers can benefit from approved drugs similar to common cancers. Molecular testing in rare cancer patients may identify treatment opportunities and clinical benefits.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

George D. Demetri et al.

Summary: This study provides additional evidence on the safety and efficacy of Entrectinib in treating NTRK fusion-positive solid tumors, with prolonged follow-up and an increased number of patients.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Review Oncology

Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism

Alessio Basolo et al.

Summary: The increasing knowledge of molecular mechanisms in cell signaling pathways has led to the discovery of tyrosine kinases, which can be targeted for anticancer therapy. Tyrosine kinase inhibitors block enzyme activity and inhibit the growth and spread of cancer, but can also cause thyroid dysfunction.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Immunotherapy in anaplastic thyroid cancer: Case series

Shyang-Rong Shih et al.

Summary: This study analyzed four cases of immunotherapy for unresectable anaplastic thyroid cancer (ATC). The results showed significant variability in treatment responses, highlighting the need for careful monitoring of both treatment efficacy and side effects in ATC patients.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Endocrinology & Metabolism

An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion

Sophie Bargas et al.

Summary: NTRK rearrangements are rare genomic abnormalities in cancers, but have a considerable frequency of 2% in thyroid cancer. This study reports a unique case of papillary thyroid carcinoma with SQSTM1-NTRK1 fusion and shows impressive clinical and radiological response to the highly specific inhibitor, larotrectinib.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

Add to Collection

Article Oncology

NTRK point mutations and their functional consequences

Corey Rogers et al.

Summary: This review focuses on NTRK gene mutations that are associated with resistance to directed therapies, mutations detected in the primary setting that confer increased oncogenic activity, and evidence that suggests that some of these variants may be treated using specific targeted therapies. The review also discusses the detection of point mutations, including the utility of cell-free DNA (cfDNA) for monitoring the acquisition of resistance mutations.

CANCER GENETICS (2022)

Add to Collection

Article Endocrinology & Metabolism

Clinical-Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma

Anello Marcello Poma et al.

Summary: This study evaluated the differences between papillary thyroid carcinoma (PTC) with different proportions of hobnail features and hobnail variant (HVPTC), finding that tumors with more than 30% hobnail areas are more likely to have distant metastasis and structural persistence, indicating the need for special attention.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Furio Pacini et al.

Summary: The use of post-operative RAI treatment for DTC should be based on patient's risk stratification. While the benefits of radioiodine are clear for high-risk patients, its use in intermediate-risk and some low-risk patients remains controversial. New guidelines have been developed, taking into consideration retrospective data and the results of prospective randomized trials, to address questions regarding patient selection, RAI activity, and pre-treatment patient preparation.

EUROPEAN THYROID JOURNAL (2022)

Add to Collection

Editorial Material Endocrinology & Metabolism

Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy

Justine Y. Bruce et al.

THYROID (2021)

Add to Collection

Article Medicine, Research & Experimental

Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion

Clare Keddy et al.

Summary: Chromosomal rearrangements of NTRK genes generate kinase fusions used in targeted therapies for various malignancies, but therapeutic resistance presents a challenge. Genetic analysis of a pediatric glioma with ETV6-NTRK3 fusion revealed new and known resistance mutations, indicating potential mechanisms contributing to resistance.

COLD SPRING HARBOR MOLECULAR CASE STUDIES (2021)

Add to Collection

Review Oncology

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research

C. Belli et al.

Summary: Aberrant activation of the RET gene drives growth in solid tumors, but current multikinase inhibitors have varying efficacy. New selective RET inhibitors show promising antitumor activity with manageable toxicity profiles in patients with RET-altered tumors.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma

Ananth Shankar et al.

Summary: A retrospective analysis was conducted on 6 untreated children with MEN2, showing significant decreases in serum calcitonin and CEA concentrations after treatment with Selpercatinib; children with measurable radiological disease experienced significant volume reduction; Selpercatinib demonstrated excellent therapeutic efficacy with minimal toxicity in children.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update

Maciej Ratajczak et al.

Summary: Thyroid cancers are among the most common tumors of the endocrine system, with a constant rise in cases observed for decades. Early diagnosis and personalized therapies, such as kinase inhibitors, are crucial for effective treatment. Despite advancements in detection and treatment, targeted treatments are being developed to improve outcomes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

V Subbiah et al.

Summary: The study revealed that RET mutations resistant to selpercatinib and pralsetinib mainly located at the solvent front and hinge regions in medullary thyroid cancer and non-small-cell lung cancer. The unconventional binding mode of selpercatinib and pralsetinib to RET avoids interference from gatekeeper mutations but is susceptible to non-gatekeeper mutations.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

Christine Dierks et al.

Summary: The combination therapy of lenvatinib and pembrolizumab may be safe and effective in patients with ATC/PDTC, resulting in complete and long-term remissions.

THYROID (2021)

Add to Collection

Review Oncology

Molecular Genetics of Follicular-Derived Thyroid Cancer

Elisabetta Macerola et al.

Summary: Thyroid tumors derived from follicular cells are heterogeneous in nature, with variable morphological appearance and differentiation levels. Molecular markers play a significant role in both diagnostic and prognostic stratification, especially in the presurgical setting and for identifying genetic alterations related to prognosis. The advent of targeted drugs has further emphasized the importance of molecular characterization in guiding therapeutic strategies for patients with advanced tumors.

CANCERS (2021)

Add to Collection

Article Endocrinology & Metabolism

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis

Daniel A. Hescheler et al.

Summary: This study identified a large number of targetable genes in PTC cases, with varied frequency of BRAF V600 mutation across different PTC subtypes. While some FDA-approved drugs can be used for treating PTC, they are only applicable to a small subset of patients.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Review Oncology

Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer

Prachi Mishra et al.

Summary: This article reviews current treatment practices for thyroid cancer and emphasizes on novel targeted molecular therapy. With rapidly expanding knowledge of the molecular biology and increased availability of genetic testing, exciting paradigm shifts in treatment strategies have been observed. Targeted therapies and personalized treatments have become a trend with the development of new treatment strategies, accelerating the advancement of treatments for thyroid cancer.

CANCERS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeted Therapies in Cancer: To Be or Not to Be, Selective

Skye Montoya et al.

Summary: Development of targeted therapies has provided nonchemotherapeutic options for patients, with small molecule kinase inhibitors being a key focus. However, resistance to these therapies may develop, necessitating multiple lines of treatment. Combinations of therapies targeting complimentary pathways may be more effective in overcoming drug resistance.

BIOMEDICINES (2021)

Add to Collection

Article Endocrinology & Metabolism

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy

Carrie C. Lubitz et al.

Summary: Thyroid cancer has seen a significant increase in incidence, with high frequencies of druggable molecular alterations, especially oncogenic driver kinase fusions, and the understanding that poorly differentiated and anaplastic thyroid carcinoma develop from more well-differentiated follicular-derived thyroid cancers. Identification of driver genomic alterations not only predicts tumor phenotype but also guides treatment approaches. Major progress in understanding the molecular underpinnings of different thyroid cancers has led to gene-specific systemic therapies and advancements in targeted therapy.

THYROID (2021)

Add to Collection

Article Endocrinology & Metabolism

2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force

Keith C. Bible et al.

Summary: The guidelines for the management of anaplastic thyroid cancer (ATC) aim to provide evidence-based recommendations to inform clinical decision-making, encompassing diagnosis, treatment goals, locoregional and advanced disease approaches, palliative care, surveillance, and ethical considerations.

THYROID (2021)

Add to Collection

Article Oncology

Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma

Antonia Afonso Povoa et al.

Summary: Papillary thyroid carcinoma (PTC) often has a good prognosis, but aggressive metastatic disease can occur in some patients. The impact of genetic alterations in BRAF, RAS, and TERT promoter (TERTp) genes on PTC patient outcomes is still controversial. Different genetic mutations may play a distinct role in predicting PTC patient outcomes, with BRAF(mut)/TERTp(wt) tumors associated with local aggressiveness and TERTp(mut) tumors predisposed to recurrent structural disease and disease-specific mortality.

CANCERS (2021)

Add to Collection

Letter Oncology

Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report

A. Matrone et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage? A multicenter experience

Assaf Moore et al.

Summary: Radioiodine-refractory thyroid cancers and anaplastic tumors have limited treatment options, but next-generation sequencing can detect clinically significant genetic alterations that benefit patients by improving survival outcomes.

MEDICINE (2021)

Add to Collection

Review Endocrinology & Metabolism

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer

Tanner Fullmer et al.

Summary: Advancements in understanding the molecular basis of thyroid function and carcinogenesis have led to the development of novel therapeutic options for iodine-resistant thyroid cancer, significantly improving the prognostic outlook for patients. FDA-approved tyrosine kinase inhibitors and small molecular inhibitors target various pathways to re-sensitize de-differentiated cancers to iodine treatment and have even provided treatment options for previously considered fatal mutations like BRAF in anaplastic thyroid cancer. The treatment landscape for iodine-resistant thyroid cancer is rapidly evolving with new targets, therapies, clinical trials, and approved treatments.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Review Oncology

Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer

Jialiang Yang et al.

Summary: Liquid biopsy, particularly circulating tumor DNA (ctDNA) testing, shows promise in diagnosing, prioritizing treatment plans, detecting residual disease, and monitoring treatment response in NSCLC patients. Studies have indicated that ctDNA testing is critical in guiding therapies for NSCLC patients, predicting clinical outcomes, monitoring response to therapies, and detecting cancer recurrence.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Precision therapy for RET-altered cancers with RET inhibitors

Kyaw Z. Thein et al.

Summary: RET is involved in physiological development and its activated mutations are potent drivers of cancer. Traditional treatment with MKIs has modest efficacy but notable toxicities. Novel RET inhibitors like selpercatinib and pralsetinib have shown success in the clinic, providing a promising future outlook.

TRENDS IN CANCER (2021)

Add to Collection

Meeting Abstract Oncology

Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: Results of the AcSe Pembrolizumab Study from Unicancer.

Sophie Leboulleux et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options

Maria Linda Rocha et al.

Summary: Anaplastic thyroid carcinoma is a rare and aggressive malignancy, and analysis of microsatellite instability (MSI) status is recommended due to potential benefits from targeted therapies. The prevalence of MSI in ATC is 7.4%, with mutations in MSH2, MSH6, and MLH1 genes being most common. Data on the prognostic value of MSI status in ATC are currently insufficient and heterogeneous.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6-NTRK3 gene fusion

Fabian Pitoia

Summary: Larotrectinib showed promising results in a patient with radioactive iodine-refractory papillary NTRK3 fusion-positive thyroid cancer, leading to a durable complete response and intracranial responses. This suggests that Larotrectinib could be a therapeutic option for patients with limited treatment choices.

CLINICAL CASE REPORTS (2021)

Add to Collection

Review Oncology

Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (Review)

Geethu Babu et al.

Summary: The incidence of differentiated thyroid cancer has increased and the prognosis is excellent, with treatment including surgery and radioactive iodine. However, treating patients non-responsive to RAI remains a challenge. Targeted therapies are showing promise in this patient population.

MOLECULAR AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Benjamin J. Solomon et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

Robert C. Doebele et al.

LANCET ONCOLOGY (2020)

Add to Collection

Letter Endocrinology & Metabolism

Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib

Laura Leroy et al.

THYROID (2020)

Add to Collection

Review Biochemistry & Molecular Biology

NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine

Federica Zito Marino et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Oncology

PD-1 Blockade in Anaplastic Thyroid Carcinoma

Jaume Capdevila et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Endocrinology & Metabolism

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

Maria E. Cabanillas et al.

THYROID (2020)

Add to Collection

Review Medicine, Research & Experimental

Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review

Andres Coca-Pelaz et al.

ADVANCES IN THERAPY (2020)

Add to Collection

Article Oncology

Improvement strategies for successful next-generation sequencing analysis of lung cancer

Kei Kunimasa et al.

FUTURE ONCOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review

Rossella Bruno et al.

DIAGNOSTICS (2020)

Add to Collection

Article Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurelien Marabelle et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

L. J. Wirth et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Oncology

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies

Alessandro Russo et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2020)

Add to Collection

Review Oncology

Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: A case report and review of literature

Victoire de Salins et al.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer

Janice M. Mehnert et al.

BMC CANCER (2019)

Add to Collection

Review Endocrinology & Metabolism

Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects

Tihana Ibrahimpasic et al.

THYROID (2019)

Add to Collection

Article Oncology

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

Ryma Benayed et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Biochemistry & Molecular Biology

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower 131i uptake in metastases

Zhaowei Meng et al.

IUBMB LIFE (2019)

Add to Collection

Article Oncology

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

C. Marchio et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Cell Biology

Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing

Huanli Duan et al.

HISTOPATHOLOGY (2019)

Add to Collection

Review Endocrinology & Metabolism

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond

Maria E. Cabanillas et al.

ENDOCRINE REVIEWS (2019)

Add to Collection

Article Oncology

Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hurthle Cell Cancer

Mehtap Derya Aydemirli et al.

CANCERS (2019)

Add to Collection

Article Multidisciplinary Sciences

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing

Raffaele Ciampi et al.

ISCIENCE (2019)

Add to Collection

Article Endocrinology & Metabolism

2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer

Laura Fugazzola et al.

EUROPEAN THYROID JOURNAL (2019)

Add to Collection

Article Oncology

Early evolutionary divergence between papillary and anaplastic thyroid cancers

J. Capdevila et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers

Nikita Pozdeyev et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

Vivek Subbiah et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Priyanka C. Iyer et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection

Article Oncology

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hurthle Cell Carcinoma

Raj K. Gopa et al.

CANCER CELL (2018)

Add to Collection

Article Oncology

Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes

Ian Ganly et al.

CANCER CELL (2018)

Add to Collection

Meeting Abstract Oncology

Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy

Saad A. Khan et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer

Xue Yang et al.

JOURNAL OF NUCLEAR MEDICINE (2017)

Add to Collection

Article Genetics & Heredity

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers et al.

GENOME MEDICINE (2017)

Add to Collection

Article Oncology

Landscape of Microsatellite Instability Across 39 Cancer Types

Russell Bonneville et al.

JCO PRECISION ONCOLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma

Bin Xu et al.

ENDOCRINE PATHOLOGY (2016)

Add to Collection

Article Medicine, Research & Experimental

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

Inigo Lancia et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Add to Collection

Review Endocrinology & Metabolism

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma

Cristina Romei et al.

NATURE REVIEWS ENDOCRINOLOGY (2016)

Add to Collection

Article Endocrinology & Metabolism

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Bryan R. Haugen et al.

THYROID (2016)

Add to Collection

Article Genetics & Heredity

Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers

Seong-Keun Yoo et al.

PLOS GENETICS (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples

Gladys Arreaza et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)

Add to Collection

Article Endocrinology & Metabolism

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

Samuel A. Wells et al.

THYROID (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Nishant Agrawal et al.

CELL (2014)

Add to Collection

Article Endocrinology & Metabolism

Outcomes in Patients With Poorly Differentiated Thyroid Carcinoma

T. Ibrahimpasic et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)

Add to Collection

Article Endocrinology & Metabolism

Hobnail Variant of Papillary Thyroid Carcinoma: An Institutional Case Series and Molecular Profile

Carrie C. Lubitz et al.

THYROID (2014)

Add to Collection

Article Pathology

Familial thyroid cancer: a review

Vania Nose

MODERN PATHOLOGY (2011)

Add to Collection

Predictive Biomarkers in Thyroid Cancer

Related references

Export Citation

Share Paper